Immunome, Inc. (IMNM) - What Are Researchers Saying About This Stock?

Key Points

• Analysts largely favor Immunome: Fifteen firms give the stock a consensus “Moderate Buy” rating, with 13 buys, one hold and one sell. The average 12-month price target is $34.25.
• Insiders have been selling shares: Company insiders sold 223,368 shares worth approximately $5.75 million over the past 90 days, while insiders retain a 7.21% ownership stake. Institutional investors own 44.58% of the stock.
• Recent performance and earnings remain challenging: IMNM opened at $18.21, below its 50-day and 200-day moving averages near $22.45, and its latest quarterly loss of $0.65 per share missed estimates of $0.51. Analysts expect a full-year loss of approximately $2.48 per share.

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $34.25.

A number of analysts have recently weighed in on IMNM shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunome in a research report on Thursday, October 15th. Wedbush reissued an "outperform" rating and set a $35.00 price target on shares of Immunome in a research report on Tuesday, October 27th. Wall Street Zen cut shares of Immunome from a "sell" rating to a "strong sell" rating in a report on Sunday, October 4th. Stifel Nicolaus began coverage on shares of Immunome in a report on Wednesday, September 30th. They issued a "hold" rating and a $24.00 price objective on the stock. Finally, Truist Financial raised their target price on shares of Immunome from $37.00 to $38.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th.

Insider Activity at Immunome

In other Immunome news, insider Jack Higgins sold 13,200 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the transaction, the insider owned 65,050 shares of the company's stock, valued at approximately $1,647,066. This represents a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the firm's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total value of $301,058.00. Following the completion of the transaction, the director directly owned 92,211 shares in the company, valued at $2,512,749.75. The trade was a 10.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 223,368 shares of company stock valued at $5,747,142 over the last ninety days. Insiders own 7.21% of the company's stock.

Institutional Trading of Immunome

Several large investors have recently added to or reduced their stakes in the business. Allworth Financial LP purchased a new position in shares of Immunome in the second quarter valued at $25,000. Integrated Wealth Concepts LLC purchased a new position in shares of Immunome during the second quarter valued at approximately $27,000. KBC Group NV bought a new position in shares of Immunome during the first quarter valued at approximately $60,000. GK Wealth Management LLC bought a new position in shares of Immunome during the third quarter valued at approximately $71,000. Finally, Sterling Capital Management LLC raised its holdings in shares of Immunome by 840.0% in the third quarter. Sterling Capital Management LLC now owns 3,478 shares of the company's stock worth $75,000 after buying an additional 3,108 shares during the period. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Performance

IMNM stock opened at $18.21 on Friday. The company has a market capitalization of $2.07 billion, a PE ratio of -7.20 and a beta of 2.55. Immunome has a one year low of $14.64 and a one year high of $30.06. The company's 50 day moving average price is $22.44 and its two-hundred day moving average price is $22.47.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.14). On average, research analysts predict that Immunome will post -2.48 EPS for the current year.

Immunome Company Profile

Immunome, Inc NASDAQ: IMNM is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines. Its technology platform analyzes human immune responses to identify antibodies that may be developed into therapies for serious diseases.

The company's research activities have included therapeutic programs in oncology and immunology, with an emphasis on antibodies designed to affect disease-driving biological pathways. Immunome has also conducted antibody discovery work related to infectious diseases, including SARS-CoV-2, as it has expanded its focus toward broader therapeutic applications.

Immunome is headquartered in Exton, Pennsylvania, and serves the global biopharmaceutical market through internal research and development activities and potential collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.